ARDENA ABOUT US

We know development.

Ardena is a CDMO and bioanalytical CRO built for the complexity of modern drug development. We specialize in drug product development, nanomedicine, and bioanalytical services - and we work exclusively with the kind of molecules that keep other CDMOs up at night.

For biotech companies pushing the boundaries of what's possible, we offer the scientific depth to match. Our drug product platform spans sterile and non-sterile dosage forms, spray drying, hot melt extrusion, and solid-state chemistry, giving us a powerful toolkit for molecules with bioavailability challenges or demanding physicochemical profiles. We bring the same rigor to HPAPIs, controlled substances, and targeted therapies with complex linker, payload, or delivery requirements.

Our nanomedicine team specializes in the formulation and manufacturing of nanoparticle-based therapeutics, one of the most technically demanding areas in drug development, and one where experience is everything.

Our bioanalytical scientists don't just generate data. They help you understand your molecule, support your regulatory strategy, and keep your program moving.

With facilities across the US and Europe, we combine the responsiveness biotech teams need with the technical firepower their molecules demand.

We know development. Let's talk about yours.

FEATURED ARTICLES

$Precision Polymorph Screening With Electron Diffraction$

Precision Polymorph Screening With Electron Diffraction

See how polymorph screening with electron diffraction uncovers hidden forms, enabling precise identification and reliable quantification of minor phases affecting performance and manufacturability.
De-Risking Drug Development: Informatics-Supported Solid Form Selection

Learn how combining polymorph screening with structural informatics improves solid‑form selection, lowers development risk, and boosts confidence in long‑term stability and manufacturability.
Mechanochemistry- Enabled Solid-State Stress Testing

Discover how solvent‑free, solid‑state stress testing speeds degradation studies, yields realistic impurity profiles, and provides earlier, material‑efficient insight into drug stability and risk.
Enhancing Safety In Drug Substance Synthesis: A Smart Approach To Chemical Design

Discover how safety‑by‑design principles in chemical synthesis help control exothermic reactions, reduce scale‑up risk, and enable safer, more reliable manufacturing of complex drug substances.
Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances

Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable, cost‑effective small molecule development.
How To Save Significantly On Early-Phase Clinical Supply

Discover how integrated clinical supply strategies streamline early trials, reduce logistics complexity, cut costs, and ensure timely delivery of investigational products and samples.
EMA Support For SMEs Through Scientific Advice And Early Dialogue

Discover how early engagement with European regulators helps smaller drug developers reduce uncertainty, clarify requirements, and de‑risk innovative programs through early dialogue.
Optimising Solubility: Selecting The Right Technology For Early Drug Development

Discover how selecting the right solubility‑enhancing technology improves early exposure, supports flexible dosing, and lays a strong foundation for downstream oral drug development.
Defining Acceptable Impurity Levels For Drug Substances In GLP Toxicology Studies

Uncover how aligning impurity profiles between toxicology and clinical drug substance builds translational confidence, supports regulatory readiness, and reduces late‑stage development risk.
(Cross-) Contamination Control Through Effective Equipment Cleaning

Discover science-driven cleaning strategies that reduce cross-contamination, enable safe multiproduct manufacturing, and support faster, flexible GMP changeovers.
The Importance Of Polymorph Screenings

Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.
Deciphering Nanoparticle Properties With AF4

Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.
Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds

Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.
Drug Substance For Early Clinical Phase Initiation

Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.
Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing

Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.
High Drug Tolerance ADA Testing For Long‑Acting mAbs

See how advanced ADA assay design overcomes extreme drug interference, enabling reliable immunogenicity assessment for long‑acting, high‑dose monoclonal antibodies in early clinical development.
Enabling Complex Phase IIa Dosing Through Flexible Clinical Packaging Design

Discover how flexible, patient‑centric clinical packaging supports complex Phase IIa dosing while protecting timelines, ensuring compliance, and avoiding costly primary packaging changes.
Advancing Nanomedicine Production With Flow Manufacturing

Learn how flow manufacturing enables scalable, reproducible nanomedicine production with tighter control, consistent particle quality, and smooth lab-to-commercial scale‑up.
Deciphering The Complex Characteristics Of Nanomedicine

Gain deeper insight into nanomedicine characterization, showing how critical quality attributes, advanced analytics, and phase‑appropriate strategies drive safety, efficacy, and regulatory readiness.
Innovations In API Manufacturing Of Small Molecule Drugs

Read how advances in people, processes, technology, materials, analytics, and sustainability are reshaping small‑molecule API manufacturing to reduce costs, scale efficiently, and meet future demand.